KEYNOTE - 641 : Study of Pembrolizumab (MK-3475) plus Enalutamide versus placebo plus Enzalutamide in participants with metastatic castraion-resistant prostate cancer (mCRPC)

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

18+Age Over 18

Prostate<br/>CancersCancer LocationProstate
Cancers

Systemic therapy | Urinary systemProstate

Trial Overview Read MoreRead more

This phase III trial is evaluating the safety and effectiveness of using a combination of a targeted therapy (Pembrolizumab) and an anti-hormonal therapy (Enzalutamide) to treat patients with metastatic castration-resistant prostate cancer..
 

This trial is treating patients with metastatic castration-resistant prostate cancer (mCRPC).

This is a systemic therapy.

You may be able to join this trial if:

  • You are able to swallow medication by mouth.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

Study of Pembrolizumab (MK-3475) plus Enalutamide versus placebo plus Enzalutamide in participants with metastatic castraion-resistant prostate cancer (mCRPC)

Commercial Sponsor

Merck

Summary

Eligible participants will receive either intravenous infusions of pembrolizumab or placebo on Day 1 of each 28-day cycle for up to 35 cycles, in addition to single daily orally administered doses of Enzalutamide.

Recruiting Hospitals Read MoreRead more

Monash Health, Medical Oncology
Clayton
Genitourinary Research Study Coordinator
gu.oncresearch@monashhealth.org
0436387664

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next